Endocrinology, Diabetes and Metabolism最新文献

{"title":"Diabetic Kidney Disease Progression Alleviated in Mice by ALKBH5-Mediated UC-MSCs-Derived Exosomes That Inhibit TRAF6 m6A Modification and Promote M2 Macrophage Polarisation","authors":"Lei Li,&nbsp;Hongmei Liu,&nbsp;Huanhuan Wang,&nbsp;Yu Mao,&nbsp;Lige Song,&nbsp;Zhiqiang Kang","doi":"10.1002/edm2.70131","DOIUrl":"10.1002/edm2.70131","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Diabetic kidney disease (DKD) is a major diabetes complication with limited treatment options. Exosomes (Exo) from umbilical cord mesenchymal stem cells (UC-MSCs) have shown therapeutic promise. The role of alkylation repair homologue protein 5 (ALKBH5)-modified UC-MSCs Exo in regulating macrophage polarisation and alleviating DKD is investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>DKD-associated inflammation was modelled by Lipopolysaccharide (LPS)/interferon-gamma (IFN-γ)-stimulated RAW264.7 macrophages. RT-qPCR and western blotting were employed to analyse mRNA and protein expression. Exosomes from ALKBH5-modified UC-MSCs were isolated and characterised. Macrophage polarisation (M1/M2) was assessed by flow cytometry, RT-qPCR, and enzyme-linked immunosorbent assay (ELISA). Tumor necrosis factor receptor-associated factor 6 (TRAF6) N6-methyladenosine (m6A) modification and expression were analysed via methylated RNA immunoprecipitation (MeRIP) and RNA immunoprecipitation (RIP) assays. The DKD model was established using spontaneous diabetic db/db mice. The renal function of mice was evaluated by ELISA and commercial assay kits. Hematoxylin–eosin (HE), periodic acid-Schiff (PAS), and Masson's trichrome staining were performed to assess the renal histopathology of mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ALKBH5 overexpression promoted M2 and inhibited M1 macrophage polarisation. ALKBH5 downregulated TRAF6 via m6A demethylation. ALKBH5-modified UC-MSCs Exo enhanced M2 polarisation and suppressed M1 phenotype in vitro. In DKD mice, ALKBH5-modified UC-MSCs Exo mitigated renal injury. Moreover, these exosomes enhanced anti-inflammatory responses and promoted M2 macrophage polarisation in DKD mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ALKBH5-modified UC-MSCs Exo reduced TRAF6 expression by demethylating its m6A sites, promoting M2 macrophage polarisation and alleviating DKD progression. These findings suggested that ALKBH5-modified UC-MSCs Exo might represent a promising therapeutic approach for DKD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70131","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Uric Acid as a Mediator of Insulin Resistance: Molecular Mechanisms and Metabolic Pathways","authors":"Nurshad Ali","doi":"10.1002/edm2.70163","DOIUrl":"10.1002/edm2.70163","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Insulin resistance (IR) is a key factor in metabolic conditions such as type 2 diabetes (T2D) and metabolic syndrome, which significantly impact global health. Serum uric acid (SUA), is the end product of purine catabolism, has increasingly been recognized as a potential modulator of insulin sensitivity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive narrative review was conducted to synthesize current evidence on SUA–mediated insulin resistance, with a focus on underlying molecular mechanisms, clinical implications, and key gaps warranting future investigation. Relevant experimental, translational, and clinical studies examining the role of SUA in insulin resistance, its mechanistic pathways, and therapeutic potential were critically analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Emerging evidence indicates that elevated SUA levels are associated with disturbances in insulin signaling pathways. Mechanistically, high SUA levels can lead to oxidative stress, endothelial dysfunction, inflammation, and impaired function of adipocytes—all of which collectively impede insulin receptor activity and downstream signaling. Key pathways involved include activation of the NLRP3 inflammasome, suppression of AMP-activated protein kinase (AMPK), and induction of mitochondrial dysfunction. These mechanisms contribute to altered insulin sensitivity in both hepatic and adipose tissues. Clinically, higher SUA levels are associated with increased risk of developing metabolic syndrome, T2D, and cardiovascular diseases, highlighting SUA's potential as both a biomarker and a therapeutic target. Despite these findings, the precise molecular interactions between SUA and insulin signaling remain incompletely understood, underscoring the need for further translational and mechanistic research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circular RNAs in Diabetic Foot Ulcers: A Scoping Review of Clinical, Preclinical, and In Silico Evidence on Diagnostic and Therapeutic Potentials","authors":"Amir Reza Ghafourian,&nbsp;Masoomeh Hamdi,&nbsp;Atefeh Soltan Mohseni,&nbsp;Maryam Davoudi,&nbsp;Hamid Choobineh,&nbsp;Fariba Nabatchian,&nbsp;Reza Afrisham","doi":"10.1002/edm2.70155","DOIUrl":"10.1002/edm2.70155","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>Diabetic foot ulcers (DFUs) involve chronic inflammation, impaired angiogenesis, oxidative stress, and disrupted fibroblast–keratinocyte interactions. Circular RNAs (circRNAs), a category of stable non-coding RNAs, have become essential regulators of these processes; nevertheless, their comprehensive functions in DFUs are still inadequately characterised. This scoping review integrated clinical, preclinical, and in silico evidence on circRNAs in DFUs to assess their diagnostic, mechanistic, and therapeutic potential.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Systematic searches of MEDLINE, EMBASE, Web of Science, and Google Scholar were conducted on July 16, 2025, according to the PRISMA-ScR guidelines. Eligible papers included clinical investigations of circRNAs in the tissues of patients with DFUs, preclinical animal models assessing circRNA-based therapies, and computational predictions of circRNA-miRNA-mRNA networks. Information was collected on circRNA expression, molecular targets, clinical associations, and therapeutic effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-two studies (7 clinical, 13 preclinical, 2 in silico) were selected. Clinical studies found <i>hsa_circ_PRKDC, hsa_circ_072697, hsa_circ_080968</i>, and <i>hsa_circ_0000907</i> to be associated with wound severity, tissue perfusion, and keratinocyte proliferation in patients with diabetic foot ulcers. Preclinical studies showed that delivery of <i>mmu_circHIPK3, mmu_circMYO9B,</i> and <i>mmu_circ_Astn1</i> via exosomes or nanoparticles improved angiogenesis, epithelial regeneration, and wound closure. However, the silence of <i>mmu_circ_0005654</i> reduced ferroptosis and inflammation. In silico analyses identified potential regulatory axes, such as <i>hsa_circ_0089761/miR-146a-5p/SMAD4</i> (<i>Mothers against decapentaplegic homologue 4</i>) and <i>hsa_circ_0049271/miR-24-3p/JUNB</i>, that were associated with inflammatory-angiogenic pathways in this disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CircRNAs hold promise for the diagnosis and treatment of DFUs by modulating angiogenesis, inflammation, oxidative stress, and epithelial repair. Standard network-guided therapies are essential to translate circRNA-based strategies into clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the NEK7/NLRP3 Inflammasome Axis: Synergistic Protection of Intravitreal MCC950 and Systemic Metformin Against Diabetic Retinopathy in Rats.","authors":"Kexuan Ren, Xiaofeng Li","doi":"10.1002/edm2.70151","DOIUrl":"10.1002/edm2.70151","url":null,"abstract":"<p><strong>Objective: </strong>Diabetic retinopathy (DR) is characterised by chronic neuroinflammation where the NLRP3 inflammasome plays a pivotal role. This study investigated the therapeutic potential and underlying mechanism of combining systemic metformin (MET) with intravitreal MCC950, a specific NLRP3 inhibitor, in a rodent model of DR.</p><p><strong>Methods: </strong>A type 2 diabetic rat model was induced by high-fat diet and streptozotocin (STZ) injection. Diabetic rats were divided into DR, MET, MCC950 and MET+MCC950 treatment groups. Body weight and blood glucose were monitored. Retinal structural changes were assessed by HE and PAS staining. Apoptosis was detected by TUNEL assay, and oxidative stress was evaluated by ROS fluorescence. The expression and interaction of key proteins within the NEK7/NLRP3 pathway were analysed by Western blot and immunofluorescence.</p><p><strong>Results: </strong>The DR group exhibited significant retinal thinning, increased acellular capillaries, elevated apoptosis and oxidative stress. While monotherapies showed partial improvement, the MET+MCC950 combination yielded the most robust protective effects, nearly restoring retinal morphology and significantly reducing apoptosis and ROS levels. Mechanistically, combination therapy most effectively suppressed the activation of the NEK7/NLRP3 inflammasome pathway, as evidenced by decreased protein levels of NEK7, NLRP3, ASC, cleaved-Caspase-1 and IL-1β. Immunofluorescence confirmed enhanced NEK7/NLRP3 interaction in DR, which was markedly inhibited by the combination treatment. A significant positive correlation was found between ROS levels and NEK7 expression.</p><p><strong>Conclusion: </strong>The study demonstrates that the combination of systemic metformin and intravitreal MCC950 confers superior protection against DR by synergistically inhibiting the NEK7/NLRP3 inflammasome pathway, resulting in reduced oxidative stress, apoptosis and inflammatory response. This novel combinational strategy presents a promising therapeutic approach for DR.</p>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":"e70151"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146054130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review","authors":"Ben Hindley,&nbsp;Sally Wright,&nbsp;Cheong Ooi,&nbsp;Ricardo Da Costa,&nbsp;Louise Cope","doi":"10.1002/edm2.70142","DOIUrl":"10.1002/edm2.70142","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The option to switch patients to more cost-effective biosimilar insulins has been available since 2014, and the market share for these medicines has been slowly increasing since then. This scoping review aimed to identify the current knowledge around stakeholder perception and experience of biosimilar insulin switches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search strategy of the published literature was conducted using several bibliographic databases including PubMed, Web of Science and CINAHL Ultimate to identify relevant articles. A grey literature search and reference scouring were also employed. A thematic analysis of the literature was then conducted to identify and synthesize findings in a narrative format.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The search identified a total of 184 records, with 20 deemed eligible for inclusion. These comprised research studies, reviews, guidance and opinion pieces with several themes identified, including healthcare professional, patient and health service administrator perspectives. Healthcare professional concerns about switching established patients, as well as patient perceptions and experiences, were highlighted as key barriers to biosimilar insulin adoption, although patients expressing strong opinions against switching were in the minority. The established nature and proven efficacy of the reference products served as a barrier to patient acceptance. Financial considerations, especially in the context of publicly funded healthcare systems, and factors expected to facilitate biosimilar insulin switches were also identified as key themes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is considerable uncertainty about how stakeholders perceive biosimilar insulin switches, particularly managed switch programmes. Almost no literature related to the experience of stakeholders who have already engaged in biosimilar insulin switching was identified. More research is needed to provide guidance on how healthcare systems can implement biosimilar insulin switch programmes in a manner acceptable to healthcare professionals and patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12750096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145858047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials","authors":"Celina R. Andonie,&nbsp;Alaaeddin Abusalameh,&nbsp;Ibrahim Ismail,&nbsp;Tamer Hodrob,&nbsp;Mahmoud Ladadweh,&nbsp;Hazem Ayesh","doi":"10.1002/edm2.70157","DOIUrl":"10.1002/edm2.70157","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>MASLD and its progressive form MASH represent a global public health challenge due to their rising prevalence and their possible progression to cirrhosis and HCC. Resmetirom, dual (e.g., cotadutide, survodutide), and triple GRAs (e.g., retarutide) have demonstrated potential efficacy in recent clinical trials. This network meta-analysis evaluates the comparative efficacy and safety of these treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We systematically searched PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central for randomised controlled trials evaluating these medications versus placebo in adults with MASLD and MASH. The outcomes assessed included changes in ALT, AST, LDL, and HDL levels, changes in MRI-PDFF, safety outcomes (diarrhoea, fatigue, and nausea), serious adverse events, ELF, adiponectin, and MASH resolution with no worsening of fibrosis. Random-effects model and network meta-analysis methods were employed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Six trials met the inclusion criteria. GRAs significantly reduced ALT levels with MD of −22.10, while resmetirom demonstrated the greatest reduction in AST levels with a MD of −13.17. Resmetirom also led to a borderline significant increase in HDL with the most significant reduction in LDL levels. Moreover, GRAs showed a significant effect on MRI-PDFF with a MD of −46.09. Overall, resmetirom showed a more favourable safety profile. In addition, GRAs significantly decreased ELF scores, resmetirom significantly improved MASH resolution without worsening of fibrosis, and both treatments significantly increased adiponectin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GRAs superiorly reduce ALT levels, MRI-PDFF, and ELF. Resmetirom significantly reduces AST, HDL, and LDL levels, increases MASH resolution without worsening of fibrosis, and offers a more favourable safety profile. Both GRAs and resmetirom significantly increase adiponectin.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12750095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145858032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real-World Assessment of Liver and Metabolic Health","authors":"Mukulesh Gupta,&nbsp;Harshita Lachhwani,&nbsp;Kumar Praful Chandra,&nbsp;Rajiv Awasthi,&nbsp;Dinesh Kumar","doi":"10.1002/edm2.70144","DOIUrl":"10.1002/edm2.70144","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a significant health concern and is commonly associated with conditions such as dyslipidemia, insulin resistance, and increased risk of cardiovascular disease. Managing MASLD requires addressing both liver and metabolic dysfunction. Saroglitazar, a dual PPARα/γ agonist, has shown potential in addressing liver steatosis, fibrosis, and dyslipidemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methodology</h3>\u0000 \u0000 <p>This prospective, single-arm, multicentric study with 50 MASLD patients with a mean age of 51.84 ± 10.66 years included 33 males. Patients received Saroglitazar magnesium 4 mg in addition to the standard of care for 6 months. The primary objective was to assess changes in liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), and secondary objectives included evaluating changes in metabolic parameters such as fasting blood glucose (FBG), postprandial blood glucose (PPBG), HbA1c, triglyceride levels, and liver enzymes (ALT, alanine aminotransferase; AST, aspartate aminotransferase) at baseline and the end of the study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A statistically significant improvement in hepatic parameters, including LSM and CAP scores, was observed. Concurrently, at the end of the study duration, 16% of patients showed improvement from liver fibrosis stages of F3/F4 to F0/F1/F2 (<i>p</i> &lt; 0.0001), and 76% of patients with severe steatosis (S3) decreased to 38% (<i>p</i> &lt; 0.0001). The key metabolic parameters also showed statistically significant reduction in FBG from 140.25 ± 51.5 mg/dL to 117.66 ± 18.17 mg/dL (<i>p</i> = 0.004), HbA1c from 7.46% ± 1.44% to 6.83% ± 1.08% (<i>p</i> = 0.0004) and triglyceride levels from 238.67 ± 168.35 mg/dL to 167.9 ± 113.89 mg/dL (<i>p</i> = 0.0001). However, during the study, anthropometric parameters remained stable, with a minor increase in BMI (28.91 ± 3.5 to 29.12 ± 3.67 Kg/m²).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Despite a slight increase in BMI, Saroglitazar significantly improved transient elastography parameters and hepatic parameters in MASLD patients, suggesting that this drug alone effectively manages MASLD-related metabolic and hepatic dysfunctions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12741649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145834838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Dietary Fatty Acid Intake With Cardiovascular Disease Risk and Serum Lipid Levels","authors":"Naeemeh Hassanpour Ardekanizadeh,&nbsp;Khadijeh Abbasi Mobarakeh,&nbsp;Sheyda Nami,&nbsp;Maryam Shojaei,&nbsp;Seyed Fazel Nasimi,&nbsp;Saba Moradi,&nbsp;Faezeh Tejareh,&nbsp;Yeganeh Shekari,&nbsp;Parsa Bahmani,&nbsp;Maryam Gholamalizadeh,&nbsp;Marjan Ajami,&nbsp;Akram Kooshki,&nbsp;Saeid Doaei","doi":"10.1002/edm2.70148","DOIUrl":"10.1002/edm2.70148","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite early interest in the effects of dietary fats on cardiovascular diseases (CVDs), substantial controversy remains regarding the evidence linking different types of fatty acids to CVDs. This study aimed to examine the association between dietary fat intake, CVD risk, and serum lipid biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study included data from 4200 adult participants (1218 patients with CVDs and 2982 healthy participants) from the Persian Cohort Study. Data on heart disease (hypertension, myocardial infarction, and ischemic heart disease) were collected. Dietary intake was assessed using a validated food frequency questionnaire (FFQ), and the intake of different fatty acids was evaluated using Nutritionist-IV software. Serum lipid profiles were analysed using enzymatic and chromatographic methods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Higher monounsaturated fatty acids (MUFA) intake showed an inverse association with CVDs (OR = 0.931, 95% CI: 0.867–0.998, <i>p</i> = 0.045). Adjustments for age, gender, smoking, alcohol consumption, physical activity, BMI, and caloric intake did not alter this association. No significant associations were observed for other dietary fats.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings suggest an inverse association between MUFA intake and CVD risk. Further longitudinal studies are warranted to confirm these results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12719392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145805683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circular RNAs as Biomarkers and Therapeutic Targets in Diabetic Cardiovascular Complications","authors":"Shreya Singh Beniwal,&nbsp;Yujin Jeong,&nbsp;Akash Rawat,&nbsp;Mahmoud Einieh,&nbsp;Kashyapi Patil,&nbsp;Rafael Everton Assunção Ribeiro da Costa,&nbsp;Pulkit Saini,&nbsp;Kamal Yousef Ghazal,&nbsp;Abhijeet Kumar,&nbsp;Ayush Dwivedi,&nbsp;Anuja Anil Mandavkar","doi":"10.1002/edm2.70149","DOIUrl":"10.1002/edm2.70149","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The global prevalence of diabetes mellitus (DM) is rising rapidly and is projected to reach unprecedented levels by 2035 and 2050, with a disproportionate burden among elderly populations and in low- and middle-income countries. Diabetes-related cardiovascular complications remain a leading cause of morbidity and mortality despite advances in glycaemic control and pharmacotherapy. There is an urgent need for novel molecular biomarkers and therapeutic targets to improve early detection, risk stratification, and personalised management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive narrative review of the current literature was conducted to summarise emerging evidence on the biological roles of circular RNAs (circRNAs) in diabetes and its cardiovascular complications. Published experimental, translational, and clinical studies investigating circRNA expression, mechanisms of action, and therapeutic potential were critically analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CircRNAs have emerged as key regulators in the pathophysiology of diabetes-associated cardiovascular disorders, including diabetic cardiomyopathy, endothelial dysfunction, and vascular inflammation, as well as related microvascular complications. Mechanistically, circRNAs act through diverse pathways such as microRNA sponging, modulation of gene transcription, interaction with RNA-binding proteins, and regulation of cellular processes including apoptosis, fibrosis, oxidative stress, and inflammation. Their covalently closed structure confers exceptional stability, while their tissue- and disease-specific expression profiles support their utility as sensitive biomarkers for early diagnosis, prognosis, and therapeutic monitoring. Advances in synthetic circRNA design further highlight their promise as novel therapeutic agents, although challenges related to delivery efficiency, specificity, and off-target effects remain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CircRNAs represent a promising class of biomarkers and therapeutic targets in diabetes-related cardiovascular complications. Their stability, specificity, and functional versatility position them as attractive tools for precision medicine approaches in diabetes care. Further mechanistic studies and well-designed clinical investigations are essential to translate circRNA-based diagnostics and therapeutics into clinical practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","authors":"Hossein Bahari,&nbsp;Maryam Sharifi,&nbsp;Zahra Nejad Shahrokh Abadi,&nbsp;Mostafa Shahraki Jazinaki,&nbsp;Haniyeh Golafrouz,&nbsp;Zahra Asadi","doi":"10.1002/edm2.70145","DOIUrl":"10.1002/edm2.70145","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Hypertension is a major cardiovascular risk factor in individuals with prediabetes and type 2 diabetes (T2D). Curcumin, with its anti-inflammatory and antioxidant properties, has emerged as a potential adjunct therapy, but its effect on blood pressure in this population remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This meta-analysis aimed to evaluate the effects of curcumin or turmeric supplementation on systolic (SBP) and diastolic (DBP) blood pressure in adults with prediabetes or T2D.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search of PubMed, Scopus, and Web of Science was conducted until August 2025. Randomised controlled trials (RCTs) investigating curcumin/turmeric supplementation on blood pressure in adults with prediabetes or T2D were included. A meta-analysis was performed using a random-effects model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifteen RCTs comprising 16 treatment arms (<i>n</i> = 855 participants) were included. Pooled results indicated that curcumin/turmeric supplementation significantly reduced SBP (WMD: −2.69 mmHg; 95% CI: −3.84 to −1.55; <i>p</i> &lt; 0.001; <i>I</i>² = 30.1%) compared to control groups. A more substantial reduction in SBP (−3.41 mmHg) was observed in the subgroup of participants with baseline hypertension (SBP ≥ 130 mmHg). However, no significant effect was found on DBP (WMD: −1.20 mmHg; 95% CI: −2.84 to 0.44; <i>p</i> = 0.15; <i>I</i>² = 84.3%). Subgroup analyses showed significant reductions in SBP in individuals with T2D or prediabetes, in those who were overweight, and with interventions using nano-curcumin, turmeric, or curcumin with piperine at doses &gt; 1 g/day. In addition, subgroup analysis showed that curcumin/turmeric supplementation led to a significant reduction in DBP in individuals with T2D.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Curcumin/turmeric supplementation demonstrates a modest, yet significant reduction in SBP in individuals with prediabetes and diabetes, with a more pronounced effect in those with baseline hypertension. Further high-quality RCTs are needed to confirm these findings and establish optimal dosing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"9 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}